Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Dulaglutide (Trulicity) vs Tiragratide
An educational, source-based comparison of Dulaglutide (Trulicity) and Tiragratide — how each peptide works, what it's researched for, and what to know before going deeper.
Once-weekly GLP-1 agonist with cardiovascular benefit.
GLP-1 analog fused to a modified human IgG4 Fc fragment, giving a half-life that supports weekly dosing. Improves glycemia and reduces MACE in T2D.
- Type 2 diabetes
- Cardiovascular risk reduction in T2D
- • FDA-approved.
- • Boxed warning: thyroid C-cell tumors in rodents.
Investigational triple hormone receptor agonist for metabolic disease.
An investigational peptide agonist targeting GLP-1, GIP, and glucagon receptors. Similar mechanism to retatrutide, designed to maximize weight loss while preserving lean mass through multi-pathway metabolic modulation.
- Obesity and metabolic syndrome
- Type 2 diabetes glycemic control
- NAFLD and liver fat reduction
- • Investigational; not yet FDA-approved.
- • Requires physician oversight in clinical trials.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Dulaglutide (Trulicity) | REWIND trial | Lancet | 2019 | Reduced major adverse cardiovascular events in T2D patients with or without prior CV disease. |
| Tiragratide | Tiragratide Phase 2 trial in obesity | Diabetes Care | 2025 | Demonstrated significant weight reduction with favorable GI tolerability profile. |
Side-effect & safety grid
- FDA-approved.
- Boxed warning: thyroid C-cell tumors in rodents.
- Investigational; not yet FDA-approved.
- Requires physician oversight in clinical trials.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Dulaglutide (Trulicity) vs Tiragratide — Key differences
- Class: Dulaglutide (Trulicity) is classified as GLP-1 Agonist · Metabolic, while Tiragratide is Metabolic · Incretin.
- Primary research focus: Dulaglutide (Trulicity) — type 2 diabetes; Tiragratide — obesity and metabolic syndrome.
- Tag: FDA-Approved · Metabolic vs Metabolic.